The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models

About Cookies on This Site

This website uses cookies. Essential and functional cookies are necessary for the proper functioning of this website and cannot be refused. Other cookies are used for statistical purposes and will only be placed if you agree to their placement. For further details on cookies, how we use cookies and how to modify your choices regarding cookies, please read our Cookies Policy.